Picankibart Trial for Palmoplantar Pustulosis, 60 Subjects, Single-Arm Open-Label Study
Summary
A prospective, single-arm, open-label clinical study of Picankibart for the treatment of palmoplantar pustulosis has been registered on ClinicalTrials.gov under NCT07552454. The trial is sponsored by the Department of Dermatology at the First Affiliated Hospital of Air Force Medical University and plans to enroll 60 eligible subjects aged 18-65 years with confirmed diagnosis. Key eligibility criteria include failure or intolerance to at least one conventional systemic agent. Exclusion criteria include active hepatitis B, hepatitis C, tuberculosis, and pregnancy.
“This study is designed as a prospective, single-arm, open-label clinical study.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
ClinicalTrials.gov has published a new trial registration for a study evaluating Picankibart as a treatment for palmoplantar pustulosis. The single-arm, open-label study plans to enroll 60 subjects aged 18-65 with confirmed diagnosis who have failed or are intolerant to at least one conventional systemic agent. The trial excludes patients with active hepatitis B, hepatitis C, tuberculosis, or pregnancy.
For pharmaceutical companies and clinical researchers, this registration signals early-stage investigation of Picankibart for a chronic inflammatory skin condition. Sponsors developing biologic or systemic therapies for palmoplantar pustulosis should monitor trial outcomes for potential competitive implications.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Picankibart in Palmoplantar Pustulosis
N/A NCT07552454 Kind: NA Apr 27, 2026
Abstract
- Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects.
- Study Subjects
Inclusion Criteria
- Aged 18-65 years, regardless of gender.
- Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and/or skin histopathology.
- Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.
- Considered suitable for treatment with Picankibart as assessed by the clinician.
- Voluntarily participate in the study and provide written informed consent.
Exclusion Criteria
- Patients with active hepatitis B, hepatitis C, or tuberculosis.
- Pregnant patients or those planning pregnancy within 6 months.
- Subjects unable to comply with follow-up as required by the study protocol.
- Other conditions deemed unsuitable for this study.
Withdrawal Criteria
- Subjects may withdraw from the study at any time for any reason.
- Occurrence of a serious adverse event or intolerable adverse event.
- Development of any item listed in the exclusion criteria during the study.
- The investigator may decide subject withdrawal for medical reasons.
Conditions: Palmoplantar Pustulosis
Interventions: Picankibart
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.